{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T16:06:18Z","timestamp":1779811578808,"version":"3.53.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100022831","name":"Sa\u011fl\u0131k Bilimleri \u00dcniversitesi","doi-asserted-by":"publisher","award":["2021\/002"],"award-info":[{"award-number":["2021\/002"]}],"id":[{"id":"10.13039\/100022831","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s13304-025-02448-y","type":"journal-article","created":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:21:13Z","timestamp":1761175273000},"page":"783-792","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of BRAF V600E and TERT mutation analysis in differential thyroid cancers"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-0213","authenticated-orcid":false,"given":"Nigar","family":"Aktash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Cem","family":"Dural","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Husnu","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuri Alper","family":"Sahbaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"Guzey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar","family":"Alt\u0131nay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cevher","family":"Akarsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1296-6369","authenticated-orcid":false,"given":"Yasir Musa","family":"Kesgin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezer","family":"Bulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Karabulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"5","key":"2448_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"12","key":"2448_CR2","first-page":"1775","volume":"5","author":"G Sithanandam","year":"1990","unstructured":"Sithanandam G, Kolch W, Duh FM, Rapp UR (1990) Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene 5(12):1775\u20131780","journal-title":"Oncogene"},{"issue":"6892","key":"2448_CR3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949\u2013954","journal-title":"Nature"},{"issue":"3","key":"2448_CR4","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1530\/ERC-15-0533","volume":"23","author":"R Liu","year":"2016","unstructured":"Liu R, Xing M (2016) TERT promoter mutations in thyroid cancer. Endocr Relat Cancer 23(3):143\u2013155","journal-title":"Endocr Relat Cancer"},{"issue":"8","key":"2448_CR5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1177\/10507256251363120","volume":"35","author":"MD Ringel","year":"2025","unstructured":"Ringel MD, Sosa JA, Baloch Z, Bischoff L, Bloom G, Brent GA et al (2025) 2025 American Thyroid Association management guidelines for adult patients with differentiated thyroid cancer. Thyroid 35(8):841\u2013985","journal-title":"Thyroid"},{"key":"2448_CR6","unstructured":"T\u00fcrkiye Cancer Statistics, Republic of T\u00fcrkiye, Ministry of Health, General Directorate of Public Health. 2018;2."},{"key":"2448_CR7","unstructured":"Cancer Stat Facts: Thyroid Cancer. National Institute of Health, Surveillance, Epidemiology, and End Results Program; 2025 [cited 2025 Sep 22]. https:\/\/seer.cancer.gov\/statfacts\/html\/thyro.html."},{"issue":"9","key":"2448_CR8","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1136\/jcp.40.9.1055","volume":"40","author":"VT Chan","year":"1987","unstructured":"Chan VT, McGee JO (1987) Cellular oncogenes in neoplasia. J Clin Pathol 40(9):1055\u20131063","journal-title":"J Clin Pathol"},{"key":"2448_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1289\/ehp.929813","volume":"98","author":"MW Anderson","year":"1992","unstructured":"Anderson MW, Reynolds SH, You M, Maronpot RM (1992) Role of proto-oncogene activation in carcinogenesis. Environ Health Perspect 98:13\u201324","journal-title":"Environ Health Perspect"},{"issue":"6","key":"2448_CR10","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/1479-7364-5-6-577","volume":"5","author":"N Naidoo","year":"2011","unstructured":"Naidoo N, Pawitan Y, Soong R, Cooper DN, Ku CS (2011) Human genetics and genomics a decade after the release of the draft sequence of the human genome. Hum Genom 5(6):577","journal-title":"Hum Genom"},{"issue":"3","key":"2448_CR11","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.surg.2021.03.056","volume":"170","author":"J Lee","year":"2021","unstructured":"Lee J, Ha EJ, Roh J, Kim HK (2021) Presence of TERT\u00b1BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma. Surgery 170(3):743\u2013747","journal-title":"Surgery"},{"issue":"6","key":"2448_CR12","first-page":"919","volume":"50","author":"T Yang","year":"2019","unstructured":"Yang T, Chen C, Pan NF, Sun LY, Jiang XL, Li JN et al (2019) BRAF V600E mutation and TERT promoter mutation in papillary thyroid carcinomas and their association with clinicopathological characteristics. Sichuan Da Xue Xue Bao Yi Xue Ban 50(6):919\u2013924","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"2448_CR13","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2147\/CMAR.S159583","volume":"10","author":"H Ren","year":"2018","unstructured":"Ren H, Shen Y, Hu D, He W, Zhou J, Cao Y et al (2018) Co-existence of BRAFV600E and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag Res 10:1005\u20131013","journal-title":"Cancer Manag Res"},{"issue":"5","key":"2448_CR14","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.3390\/cells10051082","volume":"10","author":"A Singh","year":"2021","unstructured":"Singh A, Ham J, Po JW, Niles N, Roberts T, Lee CS (2021) The genomic landscape of thyroid cancer tumourigenesis and implications for immunotherapy. Cells 10(5):1082","journal-title":"Cells"},{"issue":"44","key":"2448_CR15","doi-asserted-by":"publisher","first-page":"6646","DOI":"10.1038\/sj.onc.1208822","volume":"24","author":"TJ Giordano","year":"2005","unstructured":"Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D et al (2005) Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET\/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 24(44):6646\u20136656","journal-title":"Oncogene"},{"issue":"1","key":"2448_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1\u2013133","journal-title":"Thyroid"},{"issue":"11","key":"2448_CR17","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1089\/thy.2009.0110","volume":"19","author":"DS Cooper","year":"2009","unstructured":"Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid 19(11):1167\u20131214","journal-title":"Thyroid"},{"issue":"11","key":"2448_CR18","doi-asserted-by":"publisher","first-page":"5399","DOI":"10.1210\/jc.2003-030838","volume":"88","author":"MN Nikiforova","year":"2003","unstructured":"Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88(11):5399\u20135404","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2448_CR19","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/path.1511","volume":"202","author":"V Trovisco","year":"2004","unstructured":"Trovisco V, Vieira De Castro I, Soares P, M\u00e1ximo V, Silva P, Magalh\u00e3es J et al (2004) BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 202(2):247\u2013251","journal-title":"J Pathol"},{"issue":"2","key":"2448_CR20","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/j.1365-2265.2004.02089.x","volume":"61","author":"L Fugazzola","year":"2004","unstructured":"Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L et al (2004) BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 61(2):239\u2013243","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2448_CR21","doi-asserted-by":"publisher","first-page":"818","DOI":"10.3349\/ymj.2004.45.5.818","volume":"45","author":"KH Kim","year":"2004","unstructured":"Kim KH, Kang DW, Kim SH, Seong IO, Kang DY (2004) Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 45(5):818","journal-title":"Yonsei Med J"},{"issue":"4","key":"2448_CR22","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4132\/jptm.2020.05.12","volume":"54","author":"SY Kim","year":"2020","unstructured":"Kim SY, Kim T, Kim K, Bae JS, Kim JS, Jung CK (2020) Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans. J Pathol Transl Med 54(4):310\u2013317","journal-title":"J Pathol Transl Med"},{"issue":"5","key":"2448_CR23","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1089\/thy.2016.0350","volume":"27","author":"S Moon","year":"2017","unstructured":"Moon S, Song YS, Kim YA, Lim JA, Cho SW, Moon JH et al (2017) Effects of coexistent BRAFV600E and TERT promoter mutations on poor clinical outcomes in papillary thyroid cancer: a meta-analysis. Thyroid 27(5):651\u2013660","journal-title":"Thyroid"},{"key":"2448_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.549882","volume":"10","author":"Y Luo","year":"2020","unstructured":"Luo Y, Jiang H, Xu W, Wang X, Ma B, Liao T et al (2020) Clinical, pathological, and molecular characteristics correlating to the occurrence of radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis. Front Oncol 10:549882","journal-title":"Front Oncol"},{"issue":"3","key":"2448_CR25","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1097\/PAP.0000000000000227","volume":"26","author":"TG Papathomas","year":"2019","unstructured":"Papathomas TG, Nos\u00e9 V (2019) New and emerging biomarkers in endocrine pathology. Adv Anat Pathol 26(3):198\u2013209","journal-title":"Adv Anat Pathol"},{"issue":"Suppl 1","key":"2448_CR26","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.21037\/gs.2017.11.07","volume":"7","author":"SM Ferrari","year":"2018","unstructured":"Ferrari SM, Fallahi P, Ruffilli I, Elia G, Ragusa F, Paparo SR et al (2018) Molecular testing in the diagnosis of differentiated thyroid carcinomas. Gland Surg 7(Suppl 1):S19","journal-title":"Gland Surg"},{"key":"2448_CR27","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3389\/fendo.2019.00510","volume":"10","author":"CO Renaud","year":"2019","unstructured":"Renaud CO, Ziros PG, Chartoumpekis DV, Bongiovanni M, Sykiotis GP (2019) Keap1\/Nrf2 signaling: a new player in thyroid pathophysiology and thyroid cancer. Front Endocrinol 10:510","journal-title":"Front Endocrinol"},{"issue":"2","key":"2448_CR28","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s12020-012-9651-x","volume":"42","author":"N Kurtulmus","year":"2012","unstructured":"Kurtulmus N, Duren M, Ince U, Cengiz Yakicier M, Peker O, Ayd\u0131n O et al (2012) BRAFV600E mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness. Endocrine 42(2):404\u2013410","journal-title":"Endocrine"},{"issue":"4","key":"2448_CR29","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.path.2019.07.001","volume":"12","author":"NA Cipriani","year":"2019","unstructured":"Cipriani NA (2019) Prognostic parameters in differentiated thyroid carcinomas. Surg Pathol Clin 12(4):883\u2013900","journal-title":"Surg Pathol Clin"},{"issue":"2","key":"2448_CR30","first-page":"144","volume":"17","author":"A Sezer","year":"2017","unstructured":"Sezer A, Celik M, Bulbul BY, Can N, Tastekin E, Ayturk S et al (2017) Relationship between lymphovascular invasion and clinicopathological features of papillary thyroid carcinoma. Bosn J Basic Med Sci 17(2):144","journal-title":"Bosn J Basic Med Sci"},{"issue":"11","key":"2448_CR31","doi-asserted-by":"publisher","first-page":"3228","DOI":"10.1210\/clinem\/dgab286","volume":"106","author":"Y Tao","year":"2021","unstructured":"Tao Y, Wang F, Shen X, Zhu G, Liu R, Viola D et al (2021) BRAF V600E status sharply differentiates lymph node metastasis-associated mortality risk in papillary thyroid cancer. J Clin Endocrinol Metab 106(11):3228\u20133238","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2448_CR32","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.ejso.2016.11.003","volume":"43","author":"M Jinih","year":"2017","unstructured":"Jinih M, Foley N, Osho O, Houlihan L, Toor AA, Khan JZ et al (2017) BRAFV600E mutation as a predictor of thyroid malignancy in indeterminate nodules: a systematic review and meta-analysis. Eur J Surg Oncol EJSO 43(7):1219\u20131227","journal-title":"Eur J Surg Oncol EJSO"},{"issue":"2","key":"2448_CR33","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.surg.2014.09.003","volume":"157","author":"SY Kim","year":"2015","unstructured":"Kim SY, Kim EK, Kwak JY, Moon HJ, Yoon JH (2015) What to do with thyroid nodules showing benign cytology and BRAFV600E mutation? A study based on clinical and radiologic features using a highly sensitive analytic method. Surgery 157(2):354\u2013361","journal-title":"Surgery"},{"key":"2448_CR34","doi-asserted-by":"publisher","first-page":"1273498","DOI":"10.3389\/fendo.2023.1273498","volume":"14","author":"L Janicki","year":"2023","unstructured":"Janicki L, Patel A, Jendrzejewski J, Hellmann A (2023) Prevalence and impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto\u2019s thyroiditis: a systematic review with meta-analysis. Front Endocrinol 14:1273498","journal-title":"Front Endocrinol"},{"issue":"6","key":"2448_CR35","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00428-016-2027-5","volume":"469","author":"A Nasirden","year":"2016","unstructured":"Nasirden A, Saito T, Fukumura Y, Hara K, Akaike K, Kurisaki-Arakawa A et al (2016) In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF V600E mutation. Virchows Arch 469(6):687\u2013696","journal-title":"Virchows Arch"},{"key":"2448_CR36","first-page":"68","volume":"48","author":"OT Grati","year":"2022","unstructured":"Grati OT, Achour I, Charfi S, Chakroun A, Jdidi J, Hugonin S et al (2022) BRAF V600E mutation in differentiated thyroid carcinoma. J Tun ORL 48:68\u201373","journal-title":"J Tun ORL"},{"issue":"14","key":"2448_CR37","doi-asserted-by":"publisher","first-page":"18346","DOI":"10.18632\/oncotarget.7811","volume":"7","author":"L Jin","year":"2016","unstructured":"Jin L, Chen E, Dong S, Cai Y, Zhang X, Zhou Y et al (2016) BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget 7(14):18346","journal-title":"Oncotarget"},{"issue":"2","key":"2448_CR38","first-page":"83","volume":"35","author":"F Kombak","year":"2019","unstructured":"Kombak F, \u00d6zkan N, U\u011furlu M, Kaya H (2019) BRAFV600E immunohistochemistry in papillary thyroid carcinomas: relationship between clinical and morphological parameters. Turk J Pathol. 35(2):83\u201391","journal-title":"Turk J Pathol."},{"issue":"5","key":"2448_CR39","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/cen.13413","volume":"87","author":"HG Vuong","year":"2017","unstructured":"Vuong HG, Altibi AMA, Duong UNP, Hassell L (2017) Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma\u2014a meta-analysis. Clin Endocrinol (Oxf) 87(5):411\u2013417","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2448_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/cancers16010113","volume":"16","author":"M Abdulhaleem","year":"2023","unstructured":"Abdulhaleem M, Bandargal S, Pusztaszeri MP, Rajab M, Greenspoon H, Krasner JR et al (2023) The impact of BRAF V600E mutation allele frequency on the histopathological characteristics of thyroid cancer. Cancers 16(1):113","journal-title":"Cancers"},{"issue":"4","key":"2448_CR41","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3803\/EnM.2022.1477","volume":"37","author":"H Yang","year":"2022","unstructured":"Yang H, Park H, Ryu HJ, Heo J, Kim JS, Oh YL et al (2022) Frequency of TERT promoter mutations in real-world analysis of 2,092 thyroid carcinoma patients. Endocrinol Metab 37(4):652\u2013663","journal-title":"Endocrinol Metab"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02448-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-025-02448-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-025-02448-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T15:39:36Z","timestamp":1779809976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-025-02448-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2448"],"URL":"https:\/\/doi.org\/10.1007\/s13304-025-02448-y","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"25 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\n                      Ethical approval and consent to participate\n                      \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0This study was approved by the Institutional Ethics Committee of Bak\u0131rk\u00f6y Dr. Sadi Konuk Training and Research Hospital with protocol number 2018\/471. Informed consent to participate was obtained from all patients","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}